Hopes historic brewery will reopen this summer
A brewery which had been in operation for close to 200 years before its closure will start producing beer again.
Jennings Brewery in Cockermouth, Cumbria, was closed in November 2022 by then-owners Carlsberg Marston's Brewing Company (CMBC), which blamed economic pressures.
The site has now been bought by a local couple, Kurt and Rebecca Canfield.
"If all goes well, the site should be producing beer again by the summer," the new firm's managing director Chris France said.
Owner of local wine firm Wine and the Wood, Ms Canfield said as "lifelong residents of west Cumbria", the pair "cherished" the brewery and its beer.
"We are delighted to bring Jennings back to the local area," she said.
Mr Canfield, who is head of local engineering firm Delkia, said the building needed "critical repairs" and they had "extensive plans to enhance the site while respecting its heritage".
Mr France said the team's planned timeline for resuming beer production was reliant on those fixes.
He said there was a "rich brewing history" in the area and the team would "love to hear from anyone who wants to join the team".
The sale of the brewery included the rights to the Jennings brand and recipes, the firm said.
In November 2024, CMBC announced it would stop selling Jennings Cumberland Ale, the production of which it had moved to Staffordshire, in cask or keg format.
Bottled versions of Jennings beer will continue to be sold by Carlsberg until March, after which the rights to the brand will be transferred to Mr and Ms Canfield.
Mr France said in addition to selling the beer in bottles, the firm would sell the beer to pubs in casks.
Established as a family concern in 1828, the original Jennings brewery was located in the village of Lorton.
In 1874, having outgrown the site, the brewery moved to the banks of the river Cocker in Cockermouth.
Follow BBC Cumbria on X, Facebook, Nextdoor and Instagram. Send your story ideas to northeastandcumbria@bbc.co.uk.
Door shuts on centuries of brewing history
Town's brewing history celebrated in exhibition
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
33 minutes ago
- Bloomberg
France, Spain Agree to Advance Deliveries of Ailing Airbus A400M
Airbus SE said the governments of France and Spain agreed to fast-track some deliveries of the slow-selling A400M military transport aircraft as the main nations supporting the program seek to keep production going. France will take four aircraft sooner, while Spain will take three, Airbus said in a statement on Tuesday. Early deliveries will maintain the pace of production for the A400M, which has struggled to achieve its commercial and technical targets for years.
Yahoo
39 minutes ago
- Yahoo
Exobiosphere and Space Cargo Unlimited Unite for High-Throughput Biotech in Space
Paris Air Show, Le Bourget – June 16, 2025 – Booth B46 (Alliance NewSpace Pavilion, Paris Space Hub) PARIS, June 17, 2025 /PRNewswire/ -- Exobiosphere S.à r.l. and Space Cargo Unlimited today announced the signing of a Memorandum of Understanding (MoU) during the Paris Air Show to launch joint space missions focused on high-throughput biotechnology research. High-throughput screening (HTS) is a drug discovery process that allows for the rapid testing of thousands of chemical compounds to identify potential new medicines. The agreement signifies a shared commitment to deploy Exobiosphere's Orbital High-Throughput Screening (OHTS) platform aboard Space Cargo Unlimited's BentoBox platform across several flights, with return-to-Earth capability enabled by ATMOS' re-entry technology. The collaboration aims to offer Europe its first truly sovereign, end-to-end drug discovery and biomedical screening capability in low Earth orbit. Exobiosphere's OHTS system is able to perform a 200x more experiments than current space biotech platforms, in a standardized fashion. The system can perform thousands of autonomous cellular experiments in microgravity with each mission, with applications ranging from oncology to neurodegeneration or regenerative medicine. Space Cargo Unlimited's BentoBox, a modular orbital platform purpose-built to advance microgravity research and in-space manufacturing, will host Exobiosphere's payloads and provide, across the series of missions planned, a growing number of defining services to best support OHTS performance and future developments based upon customer needs. This will include real-time data control, AI-powered software support, thermal-management and anti-vibration systems—bringing researchers closer to the experiment than traditional, human crewed stations, which often come with long-wait times, constrained operations, and limited control. "With this MoU, we're creating Europe's first fully integrated bio-research mission architecture," said Kyle Acierno, CEO of Exobiosphere. "From ground to orbit and back, Exobiosphere and Space Cargo Unlimited are building the next frontier of pharmaceutical innovation—faster, more accurate, and truly sovereign. This is a major step forward for European biotech leadership in space." The first joint mission is targeted for launch in 2026. Exobiosphere will contribute its autonomous screening payload, capable of executing over 2,000 cellular assays per mission. The OHTS will be integrated into BentoBox, which will be carried first aboard Phoenix—a re-entry capable, small-scale free-flyer developed by ATMOS-, and ultimately REV1, full-scale free flyer developed by Space Cargo Unlimited to enable frequent and cost-effective research in space. "Space Cargo Unlimited has always believed that space is the next frontier for biotechnology," said Nicolas Gaume, CEO of Space Cargo Unlimited. "Partnering with Exobiosphere allows us to concretely deliver on this promise. Our BentoBox platform, with its defining subsystems and frequent schedule of launch, paired with the OHTS system, offers pharmaceutical and life science customers across Europe a dedicated, autonomous orbital lab. It delivers real-time data and greater control than legacy ISS-based methods, along with the speed and repeatability needed to bring space biotech to market." This partnership comes at a time of accelerating demand for microgravity-enabled health technologies. Studies have shown that cells behave differently in space, exhibiting accelerated growth, aging, and drug response—key factors that improve the predictive power of pre-clinical models. Exobiosphere's OHTS takes advantage of these phenomena by offering automated, scalable high-throughput testing that would otherwise take months or years to replicate on Earth. By combining Space Cargo Unlimited's logistics and infrastructure with Exobiosphere's biotechnology expertise, the companies are creating a unique ecosystem that can serve pharmaceutical, academic, and government stakeholders seeking novel R&D capabilities. This agreement at Paris Air Show reflects both companies' commitment to advancing European autonomy in space-based science and to making space a viable laboratory for the next generation of therapies. Media Contact: ExobiosphereInfo@ Space Cargo Unlimitededoyle@ About Exobiosphere Exobiosphere is the world's first contract research organization dedicated to high-throughput testing and drug discovery in space. By combining space-grade lab automation, microgravity research, and advanced analytics, the company helps pharmaceutical, biotech, and healthcare partners enhance scientific discovery and accelerate product development. Its Orbital High-Throughput Screening Device (OHTS) is designed to uncover novel cellular and disease behaviors in a microgravity environment—insights that are difficult or impossible to replicate on Earth. Headquartered in Luxembourg at the House of BioHealth, Exobiosphere's mission is to shorten R&D timelines and bring safer, more effective treatments to market for patients worldwide. About Space Cargo Unlimited Space Cargo Unlimited is developing the next generation of European space infrastructure to deliver autonomous, return-capable missions to low Earth orbit. Its BentoBox platform is a modular in-orbit laboratory and production facility engineered to support microgravity research, in-space manufacturing, and technology demonstration at commercial scale. Designed from the ground up to maximize control, data access, and repeatability, Space Cargo Unlimited enables scientific and industrial users to test, build, and return new discoveries from space. Headquartered in Luxembourg with a growing ecosystem of European partners, Space Cargo Unlimited's mission is to unlock the full value of microgravity for applications on Earth. Photo - View original content to download multimedia: SOURCE Space Cargo Unlimited; Exobiosphere
Yahoo
39 minutes ago
- Yahoo
Winner of the 'Biotherapies and Bioproduction' call for projects under the France 2030 plan, EVerZom receives €3 million in government funding to industrialize its exosome bioproduction technology
Winner of the 'Biotherapies and Bioproduction' call for projects under the France 2030 plan, EVerZom receives €3 million in government funding to industrialize its exosome bioproduction technology Paris, June 17, 2025 – EVerZom, a French biopharmaceutical company pioneering exosome-based therapies for regenerative medicine applications, has announced it has received €3 million in funding as part of the France 2030 plan, through the 'Biotherapies and Bioproduction of Innovative Therapies' call for projects, operated by Bpifrance on behalf of the French government. This financial support will enable the company to accelerate the industrialization of its exosome bioproduction platform to develop its proprietary and co-developed drug candidates. Accelerating the transition to late-stage clinical production and commercialization This funding marks a key step in the company's industrial scale-up. It will notably allow for the scale-up of its exosome bioproduction technology in 50L GMP bioreactors, reaching a production level compatible with late-stage clinical phases and market launch. 'The French government 's support through the France 2030 'Biotherapies and Bioproduction' call is a strong recognition of our technology and industrial ambition. Thanks to this funding, we will secure a robust and scalable bioproduction process, which is essential to advance through late-stage clinical phases and prepare the market entry of our future proprietary or co-developed treatments,' said Jeanne Volatron, CEO of EVerZom. Exosomes at the heart of the development of promising new biotherapies Exosomes are tiny biological vesicles (30 to 150 nanometers) naturally secreted by cells. They play a key role in intercellular communication, transporting proteins, messenger RNAs, and other functional biomolecules between cells. EVerZom leverages exosomes derived from mesenchymal stem cells, known for their regenerative and immunomodulatory properties. Compared to the cells themselves, exosomes offer numerous advantages: increased stability, reduced variability, enhanced patient safety, and simplified logistics (direct hospital storage and immediate availability). EVerGel, EVerZom's first drug candidate for Crohn's disease EVerZom's flagship program, EVerGel, combines exosomes with an innovative hydrogel biomaterial, enabling prolonged release at the site of complex perianal fistulas—a debilitating condition associated with Crohn's disease that affects nearly 2 million patients worldwide. Initial preclinical results are highly promising: in a porcine model close to the human condition, EVerGel achieved complete healing in 87.5% of cases after 4 weeks, compared to just 12.5% in the control group. Thanks to these results, the drug candidate could enter clinical trials as early as 2026, with a target commercialization date for 2030. High potential far beyond the targeted indications Ultimately, the potential of exosome therapies to regenerate tissue and modulate inflammatory processes opens the door to new applications in a variety of fields, including neurodegenerative diseases, age-related disorders, and regenerative cosmetics. In this context, EVerZom has established around twenty global partnerships with players in human health, animal health, and cosmetics. Press contact : Florence Portejoie, FP2COM, 06 07 76 82 83, fportejoie@ About EVerZom Founded in 2019, EVerZom develops exosome-based treatments derived from mesenchymal stem cells, combined with biomaterials for targeted applications. With a proprietary technology for the production and purification of exosomes, EVerZom aims to address unmet medical needs in chronic inflammatory and degenerative diseases. The company relies on cutting-edge scientific expertise, a network of industrial and academic partners, and a development model focused on pharmaceutical quality and industrialization. This €3 million funding is part of the France 2030 plan, a French government initiative endowed with €54 billion to support breakthrough innovations and the emergence of technology champions in strategic sectors such as biotechnology. About France 2030 ✔ Embodies a dual ambition: to sustainably transform key sectors of our economy (health, energy, automotive, aerospace, and space) through technological innovation, and to position France not just as a player but as a leader in the world of tomorrow. From basic research to the emergence of an idea through to the production of a new product or service, France 2030 supports the entire innovation lifecycle up to industrialization. ✔ Is unprecedented in its scope: €54 billion are being invested to help our companies, universities, and research organizations successfully transition in these strategic sectors. The goal is to enable them to competitively tackle ecological and attractiveness challenges and foster the emergence of future leaders in our fields of excellence. France 2030 has two transversal objectives: dedicating 50% of its spending to the decarbonization of the economy and 50% to emerging players carrying innovations that are not harmful to the environment (in line with the Do No Significant Harm principle). ✔ Is implemented collectively: designed and deployed in consultation with economic, academic, local, and European stakeholders to determine strategic orientations and flagship actions. Project leaders are invited to submit their applications through open, rigorous, and selective procedures to benefit from State support. ✔ Is managed by the General Secretariat for Investment on behalf of the Prime Minister and implemented by the French Environment and Energy Management Agency (ADEME), the National Research Agency (ANR), Bpifrance, and the Banque des Territoires. More information: | @SGPI_avenir About the 'Innovations in Biotherapies and Bioproduction' call for projects The 'Innovations in Biotherapies and Bioproduction' call for projects is a support mechanism within the framework of the 'Biotherapies and Bioproduction of Innovative Therapies' acceleration strategy of France 2030, led by the Health Innovation Agency within the General Secretariat for Investment. Its objective is to catalyze and sustain excellence in biotherapy research by accelerating technology transfer and ensuring a constant flow of innovations from bench to bedside. About Bpifrance Bpifrance finances businesses at every stage of their development with loans, guarantees, and equity. It supports their innovation and international projects. Bpifrance also backs their export activities through a broad range of products. Advisory services, training, networking, and acceleration programs for startups, SMEs, and mid-caps are also part of the offering. Thanks to Bpifrance and its 50 regional offices, entrepreneurs benefit from a close, single, and efficient contact to support them and help them meet their challenges. More information: - - Follow us on X (formerly Twitter): @Bpifrance - @BpifrancePresse and on LinkedIn Attachment Everzom_PR_Winner_France_2030_VDEF
